Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Samir H. Barghout"'
Autor:
Samir H. Barghout
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 21:214-230
Drug discovery in the scope of cancer therapy has been focused on conventional agents that nonselectively induce DNA damage or selectively inhibit the activity of key oncogenic molecules without affecting their protein levels. An emerging therapeutic
Autor:
Anna Rydlewski, Jaime O. Claudio, Karen Yee, Andre C. Schuh, Aaron D. Schimmer, Mahadeo A. Sukhai, Sanduni U. Liyanage, Thirushi P. Siriwardena, Mark D. Minden, Rose Hurren, Dawn Maze, Samir H. Barghout, Steven M. Chan, Amr Rostom, Hassan Sibai, Emily Heath, Dina Khalaf, Vikas Gupta, Marcela Gronda, Tracy Stockley, Tong Zhang, Andrzej Lutynski, Simon Kavanagh, Suzanne Kamel-Reid
Publikováno v:
Leukemia research. 68
We evaluated outcomes of 100 patients with high risk AML treated with Ida-FLAG induction as first-line therapy. 72 achieved remission with one cycle; 19 did not. High risk cytogenetics and TP53 mutations were associated with failure to achieve remiss
Autor:
Yang Xin Fu, Lynne-Marie Postovit, Samir H. Barghout, Christine Yang, Abul K. Azad, Nubia Zepeda, Helen Steed, Krista Vincent, Zhihua Xu
Publikováno v:
Gynecologic oncology. 138(3)
Objective Resistance to platinum-based therapeutic agents represents a major hurdle in the treatment of epithelial ovarian cancer (EOC). There is an urgent need to better understand the underlying mechanisms. Here, we investigated the role of RUNX3 i